• Recombinant Annexin V for Apoptosis Detection

  2026-09-19

  Brumatti, Sheridan, and Martin established a practical workflow for producing soluble, polyhistidine-tagged recombinant annexin V in Escherichia coli, followed by FITC conjugation and use in apoptosis assays. The study is valuable because it connects accessible protein production with phosphatidylserine detection by flow cytometry and fluorescence microscopy, while clarifying the membrane biology underlying the readout.

• 2-NBDG Glucose Uptake Assay Kit for HCC

  2026-09-18

  The 2-NBDG Glucose Uptake Assay Kit enables rapid, non-radioactive mapping of glucose transport in bulk cultures, organoids, and single cells. Its fluorescence-based workflow adds a practical metabolic layer to hepatocellular carcinoma studies investigating HNF4A-AS1, sorafenib response, and lipid-driven ferroptosis.

• 2-Thio-dCTP: DNA Assay Workflows

  2026-09-18

  Build more informative DNA polymerase and DNA–protein interaction assays with 2-Thio-dCTP, a sulfur-substituted cytidine triphosphate designed for controlled nucleotide incorporation. This guide connects practical DNA modification workflows with the SCP4–H3T3 chromosome-stability pathway while clearly separating established evidence from exploratory applications.

• BML-277: Chk2 Inhibition as a Causal Probe

  2026-09-17

  BML-277 is a potent Chk2 inhibitor for dissecting DNA damage signaling beyond simple kinase readouts. This article connects the nuclear cGAS–TRIM41–ORF2p discovery to assay design, causal inference, and carefully bounded applications in T-cell radioprotection and cancer research.

• BML-277 and the Chk2–cGAS Genome Integrity Axis

  2026-09-17

  A translational perspective on using BML-277 to dissect Chk2 signaling, nuclear cGAS biology, T-cell radioprotection, and genome stability while separating established evidence from testable hypotheses.

• LY2603618 Chk1 Inhibitor Workflow Guide

  2026-09-16

  Build reproducible DNA-damage and cell-cycle assays with LY2603618, a selective Chk1 inhibitor suited to replication-stress and chemotherapy-sensitization studies. This workflow connects practical dosing with redox and nucleotide-pool biomarkers that can explain why NSCLC models respond differently.

• LNP Surface Charge and V-ATPase Drive Nucleic Acid Delivery

  2026-09-16

  The reference study proposes that lipid nanoparticle tropism is determined by a cooperative interaction between LNP surface charge and the endo/lysosomal V-ATPase activity of target cells. Its in vitro and in vivo experiments show that cellular state can redirect delivery between liver and lung, providing a mechanistic framework for interpreting LNP performance beyond particle composition alone.

• PDE4B, AMPK, and Endothelial Dysfunction in Hypertension

  2026-09-15

  The reference study identifies PDE4B as a stress-associated driver of angiotensin II-induced endothelial injury and connects its silencing to restoration of AMPK/Sirt1/Nrf2/ARE signaling. Its use of Compound C as a pathway challenge strengthens the mechanistic interpretation, while also showing why pharmacological inhibition should be combined with genetic and functional assays.

• Mitoxantrone Targets the ERα DBD–LBD Interface

  2026-09-15

  Wang et al. identify an allosteric mechanism by which mitoxantrone binds the estrogen receptor alpha DBD–LBD interface, drives cytoplasmic redistribution and proteasomal degradation, and suppresses endocrine-resistant ERα signaling. The study provides a preclinical framework for targeting receptor interdomain communication rather than competing directly with estrogen at the ligand-binding pocket.

• Metabolic Readouts for Sorafenib-Resistant HCC

  2026-09-14

  A translational framework for using fluorescent glucose uptake measurements to investigate metabolic plasticity, sorafenib resistance, and lipid-driven ferroptosis in hepatocellular carcinoma models.

• Fenofibrate, Aging Mice, and PPARα–YAP Signaling

  2026-09-14

  The reference study shows that Fenofibrate induces comparable liver enlargement and activates the PPARα–YAP axis in adult and aging mouse models. By combining chemically induced, naturally aged, and senescence-accelerated mice, the work suggests that this hepatic response is broadly preserved with age while also clarifying the limits of translating mouse liver remodeling to elderly patients.

• MRT68921: A Causal Framework for ULK1 Assays

  2026-09-13

  MRT68921 is a dual ULK1/2 kinase inhibitor for dissecting autophagy initiation. This article explains how energy stress, AMPK biology, ATG13 phosphorylation blockade, and LC3 flux measurement should shape experimental interpretation.

• PD 0332991 in Gastric Cancer Assembloids

  2026-09-12

  Use PD 0332991 to test CDK4/6-dependent cell-cycle control in matched gastric tumor organoids and stromal assembloids. The workflow separates tumor-intrinsic sensitivity from microenvironment-mediated resistance, enabling more realistic drug-response comparisons.

• Niclosamide STAT3 Research Workflows

  2026-09-11

  Niclosamide connects STAT3 Tyr-705 inhibition with apoptosis, cell-cycle, and NF-κB readouts in cancer research. This workflow also uses ATRX-stratified glioma findings to improve comparative screening without overstating evidence for cross-pathway combinations.

• Ribociclib Succinate: From CDK4/6 Biology to Translation

  2026-09-11

  A translational framework for using LEE011 succinate as a CDK inhibitor: connect cell cycle regulation, orthogonal assay design, pH-aware formulation, and breast cancer research strategy without confusing in vitro activity with clinical exposure.

8104 records 1/541 page Next 12345 下5页 Last page